KRAS mutations occurred in 10% of the Rn-exposed cohort and in 7% in the non-exposed cohort; both percentages are below pre-described frequencies of 29.7% of NSCLC-patients in the AACR project [36]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.